Tredje AP fonden Has $1.65 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Tredje AP fonden decreased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,337 shares of the life sciences company's stock after selling 12,336 shares during the quarter. Tredje AP fonden's holdings in Illumina were worth $1,649,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in ILMN. Versant Capital Management Inc boosted its position in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares during the period. Golden State Wealth Management LLC bought a new stake in Illumina during the fourth quarter worth approximately $32,000. Assetmark Inc. boosted its position in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Illumina during the fourth quarter worth approximately $45,000. Finally, TD Private Client Wealth LLC boosted its position in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after purchasing an additional 141 shares during the period. Institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Royal Bank of Canada cut their price target on Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a report on Wednesday, March 12th. Stephens reiterated an "overweight" rating and set a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. Piper Sandler upped their price target on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. TD Cowen lowered Illumina from a "buy" rating to a "hold" rating and cut their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Robert W. Baird cut their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Illumina currently has a consensus rating of "Moderate Buy" and a consensus target price of $140.90.

Remove Ads

Illumina Price Performance

Shares of ILMN stock traded down $0.20 during trading hours on Wednesday, hitting $84.96. 2,612,128 shares of the company's stock were exchanged, compared to its average volume of 2,583,026. The stock's 50-day moving average is $111.38 and its 200-day moving average is $129.20. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The stock has a market cap of $13.46 billion, a price-to-earnings ratio of -11.06, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.